Zimmer Biomet (ZBH) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with gratitude to employees and shareholders, emphasizing the company's transformation and ongoing strategic priorities for 2026.

• Agenda included a business update, formal business proceedings, and a Q&A session with shareholders.

Strategic initiatives and plans

• Continued focus on people and culture, operational excellence, and innovation/diversification.

• Emphasis on specialized U.S. sales channels and new go-to-market strategies to boost competitiveness in high-growth segments like robotics and S.E.T.

• Innovation pipeline has doubled, with new products such as the Oxford Partial Cementless Knee and Monogram AI-driven robotic system expected in 2027.

• Completion of U.S. commercial changes and Monogram launch planned by end of 2027, aiming for higher market growth rates.

Financial performance review

• Disciplined cost management supports earnings per share growth and ongoing investment.

• Free cash flow expected to grow in the upper single-digit to double-digit range.

• Increased share repurchase expectations to $1 billion for the year, prioritizing capital return over M&A.